» Articles » PMID: 34501219

PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Sep 10
PMID 34501219
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The implementation of clinical pharmacogenetics in daily practice is limited for various reasons. Today, however, it is a discipline in full expansion. Accordingly, in the recent times, several initiatives promoted its implementation, mainly in the United States but also in Europe. In this document, the genotyping results since the establishment of our Pharmacogenetics Unit in 2006 are described, as well as the historical implementation process that was carried out since then. Finally, this progress justified the constitution of La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics (PriME-PGx), promoted by the Clinical Pharmacology Department of Hospital Universitario de La Princesa (Madrid, Spain). Here, we present the initiative along with the two first ongoing projects: the PROFILE project, which promotes modernization of pharmacogenetic reporting (i.e., from classic gene-drug pair reporting to complete pharmacogenetic reporting or the creation of pharmacogenetic profiles specific to the Hospital's departments) and the GENOTRIAL project, which promotes the communication of relevant pharmacogenetic findings to any healthy volunteer participating in any bioequivalence clinical trial at the Clinical Trials Unit of Hospital Universitario de La Princesa (UECHUP).

Citing Articles

Effect of Genetic Variants on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Involvement of , and .

Gonzalez-Iglesias E, Mendez-Ponce C, Ochoa D, Roman M, Mejia-Abril G, Martin-Vilchez S Int J Mol Sci. 2025; 26(1.

PMID: 39796117 PMC: 11720188. DOI: 10.3390/ijms26010260.


Evaluation of the role of metabolizing enzymes and transporter variants in ezetimibe pharmacokinetics.

Gonzalez-Iglesias E, Ochoa D, Navares-Gomez M, Zubiaur P, Aldama M, de la Torre T Front Pharmacol. 2024; 15:1414059.

PMID: 39484171 PMC: 11524821. DOI: 10.3389/fphar.2024.1414059.


Pharmacogenomics and Big Data in medical oncology: developments and challenges.

Marcu L, Marcu D Ther Adv Med Oncol. 2024; 16:17588359241287658.

PMID: 39483136 PMC: 11526290. DOI: 10.1177/17588359241287658.


Genetic Variation in , , and Alters the Pharmacokinetics and Safety of Mirabegron.

Soria-Chacartegui P, Cendoya-Ramiro P, Gonzalez-Iglesias E, Martin-Vilchez S, Rodriguez-Lopez A, Mejia-Abril G Pharmaceutics. 2024; 16(8).

PMID: 39204422 PMC: 11359404. DOI: 10.3390/pharmaceutics16081077.


Update on the PriME-PGx initiative: evolution of pharmacogenetics in daily clinical practice.

Gonzalez-Iglesias E, Abad-Santos F Pharmacogenomics. 2024; 25(8-9):401-406.

PMID: 39115196 PMC: 11418291. DOI: 10.1080/14622416.2024.2375188.


References
1.
Fragoulakis V, Roncato R, Dalle Fratte C, Ecca F, Bartsakoulia M, Innocenti F . Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity. Am J Hum Genet. 2019; 104(6):1158-1168. PMC: 6557730. DOI: 10.1016/j.ajhg.2019.04.017. View

2.
Caudle K, Thorn C, Klein T, Swen J, McLeod H, Diasio R . Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013; 94(6):640-5. PMC: 3831181. DOI: 10.1038/clpt.2013.172. View

3.
Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D . Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94(3):317-23. PMC: 3748366. DOI: 10.1038/clpt.2013.105. View

4.
Hinderer M, Boeker M, Wagner S, Lablans M, Newe S, Hulsemann J . Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development. BMC Med Inform Decis Mak. 2017; 17(1):81. PMC: 5461630. DOI: 10.1186/s12911-017-0480-y. View

5.
Phillips E, Sukasem C, Whirl-Carrillo M, Muller D, Dunnenberger H, Chantratita W . Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther. 2018; 103(4):574-581. PMC: 5847474. DOI: 10.1002/cpt.1004. View